Biotech
Synthego
Synthego raises $200M Series C at $1.2B valuation
$200M
Total Raised
Series C
Latest Round
2012
Founded
200+
Employees
3565 Haven Avenue, Redwood City, CA 94063
1 min read
Quick Facts
Valuation
$1.2B
Latest Round Size
$200M
Latest Round Date
June 2024
Synthego: Series C Funding Round
Synthego has successfully raised $200M in Series C funding, reaching a valuation of $1.2B.
Company Overview
CRISPR genome engineering tools
Funding Details
The Series C round was led by Founders Fund, with participation from 8VC, Menlo Ventures, Paladin Capital Group, Tencent.
Company Information
- Headquarters: 3565 Haven Avenue, Redwood City, CA 94063
- Founded: 2012
- Employees: 200+
- Category: Biotech
Investment
Synthego plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Founders Fund: Verified investor in Series C
- 8VC: Verified investor in Series C
- Menlo Ventures: Verified investor in Series C
- Paladin Capital Group: Verified investor in Series C
- Tencent: Verified investor in Series C
Key Investors
Founders Fund
Lead Investor
Verified investor in Series C
8VC
Investor
Verified investor in Series C
Menlo Ventures
Investor
Verified investor in Series C
Paladin Capital Group
Investor
Verified investor in Series C
Tencent
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M